PROCEPT BioRobotics Corporation Securities Fraud Class Action Update for Investors

Update on PROCEPT BioRobotics Corporation Securities Fraud Class Action

On August 10, 2026, Kessler Topaz Meltzer & Check, LLP announced a significant development for investors in PROCEPT BioRobotics Corporation. A class action lawsuit alleging securities fraud has been filed, impacting all individuals who purchased common stock in PROCEPT between February 28, 2024, and February 25, 2026. This lawsuit, officially documented in the United States District Court for the Northern District of California, seeks to address concerns regarding the alleged misstatements made by the company's management about product demand.

Background

PROCEPT BioRobotics Corporation is a medical technology company focused on developing advanced treatments for benign prostatic hyperplasia (BPH), commonly known as enlarged prostate. During the specified class period, the company marketed an Aquablation therapy system, which utilizes a single-use handpiece that is discarded after each procedure.

The lawsuit points out that throughout the designated class period, the company made various materially false statements about its business practices and prospects. Specific allegations include the company's use of a discount program that incentivized bulk orders exceeding actual demand, thereby inflating reported sales figures. Furthermore, it is alleged that this practice led to significant overstocking, exposing the company to undisclosed risks both operationally and financially.

Stock Price Impact

On February 25, 2026, PROCEPT released its financial earnings for the fiscal year of 2025 and the first quarter of 2026, revealing that handpiece sales had outstripped procedural needs consistently since the first fiscal quarter of 2023. Despite reassurances to the contrary prior to this announcement, the market reacted negatively, causing the stock price to plummet by over 18% following this news.

What Should Affected Investors Do?

Investors who have experienced losses due to their investment in PROCEPT are encouraged to take action. Key Steps Include:
1. Filing for Lead Plaintiff Status: Interested parties should file to become a lead plaintiff by the September 22, 2026 deadline. Being a lead plaintiff enables individuals to represent the class in the lawsuit.
2. Contact Kessler Topaz Meltzer & Check, LLP: Investors can reach out to the firm for a complimentary case evaluation. All legal representation is provided on a contingency basis, which means no upfront costs for investors seeking to recover losses.
3. Deciding on Legal Action: Affected parties can choose to retain their counsel or opt to remain passive within the class action. The choice of whether to actively participate as a lead plaintiff does not influence one's potential recovery from the case.

Conclusion

The situation surrounding PROCEPT BioRobotics serves as a strong reminder for investors to remain vigilant about the companies they support. The ongoing class action lawsuit may provide an avenue for recovery for those who have lost money due to potential securities fraud. Kessler Topaz Meltzer & Check, LLP invites any individual or institution affected by this matter to reach out for guidance and support on how to proceed.

For more information, interested parties can use the contact details provided earlier or visit Kessler Topaz Meltzer & Check's website for further details.